Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's ANDA activity

Executive Summary

Generic Drugs Division ANDA "actions," including approvals, increased from 2,149 in 1984 to 5,379 in 1985 to 7,430 in 1986, according to agency data distributed at a Nov. 3-4 Pharmaceutical Manufacturers Association meeting. Actual ANDA approvals during the same three years increased from 382 to 389 to 616. Original ANDAs filed with FDA jumped from 470 in 1984 (when the post-1962 ANDA/patent extension law was enacted) to 1,069 in 1985 and 1,062 in 1986; 814 of the ANDA filed in 1986 have been for post-1962 products. Post-1962 approvals have been granted to 14 brandname and 41 generic drug manufacturers since the law was passed. Eight of the generic firms received first-ever post-1962 ANDAs.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS010993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel